

Supplementary Table 2. Impact of acid-suppressant type on successful eradication according to clarithromycin-resistance mutation

Variable	Rabeprazole-based therapy (n=24)	Tegoprazan-based therapy (n=48)	<i>p</i> -value
Clarithromycin resistance mutation*			
Absence, n/N (%)	14/16 (87.5)	24/30 (80.0)	0.189
Presence, n/N (%)	2/8 (25.0)	10/18 (55.6)	0.216

Only patients who received 14-day triple or 10-day concomitant therapy were included in this analysis.

*This indicates A2142G or A2143G mutation.

n, number of patients with successful *H. pylori* eradication; N, number of patients.